Durvalumab-Based Treatment Before and After Surgery Improved Outcomes for Patients with Resectable Non-Small Cell Lung Cancer (NSCLC); Patients Treated with Durvalumab-Based Regimen Before and After Surgery in the AEGEAN Trial Had a 32% Reduction in Risk of Disease Recurrence or Progression Events

Patients with treatment-naïve resectable non-small cell lung cancer (NSCLC) who
received neoadjuvant durvalumab (Imfinzi) plus chemotherapy and adjuvant durvalumab monotherapy had improved event-free survival (EFS) and pathological complete response (pCR) compared with those who received neoadjuvant chemotherapy alone, according to results from the phase III placebo-controlled AEGEAN clinical trial, which were presented (CT005) at the American Association for Cancer Research (AACR) Annual Meeting 2023, held April 14-19 in Orlando, Florida.

Login Or Register To Read Full Story